Dane Leone

Stock Analyst at Raymond James

(1.62)
# 3,222
Out of 4,761 analysts
88
Total ratings
38.24%
Success rate
-5.72%
Average return

Stocks Rated by Dane Leone

Xilio Therapeutics
Nov 8, 2024
Maintains: Outperform
Price Target: $6$4
Current: $0.93
Upside: +330.11%
REGENXBIO
Feb 21, 2024
Reinstates: Outperform
Price Target: $45
Current: $7.27
Upside: +518.98%
Blueprint Medicines
Dec 22, 2023
Maintains: Strong Buy
Price Target: $85$100
Current: $92.25
Upside: +8.40%
Revolution Medicines
Nov 16, 2023
Initiates: Outperform
Price Target: $30
Current: $41.34
Upside: -27.43%
bluebird bio
Nov 8, 2023
Maintains: Outperform
Price Target: $200$260
Current: $4.08
Upside: +6,272.55%
Regeneron Pharmaceuticals
Nov 3, 2023
Upgrades: Outperform
Price Target: $950
Current: $700.33
Upside: +35.65%
Nkarta
Oct 18, 2023
Upgrades: Strong Buy
Price Target: $13
Current: $2.05
Upside: +534.15%
BridgeBio Pharma
Jul 18, 2023
Maintains: Outperform
Price Target: $29$46
Current: $36.85
Upside: +24.83%
Galapagos NV
May 8, 2023
Upgrades: Outperform
Price Target: $69
Current: $26.74
Upside: +158.04%
Relay Therapeutics
Apr 19, 2023
Upgrades: Strong Buy
Price Target: $29
Current: $3.92
Upside: +639.80%
Maintains: Outperform
Price Target: $5$8
Current: $2.92
Upside: +173.97%
Maintains: Strong Buy
Price Target: $29$14
Current: $7.00
Upside: +100.00%
Upgrades: Strong Buy
Price Target: $58
Current: $15.74
Upside: +268.49%
Maintains: Outperform
Price Target: $54$70
Current: $31.77
Upside: +120.33%
Downgrades: Market Perform
Price Target: n/a
Current: $2.17
Upside: -
Maintains: Outperform
Price Target: $54$63
Current: $50.26
Upside: +25.35%
Downgrades: Market Perform
Price Target: n/a
Current: $55.83
Upside: -
Downgrades: Market Perform
Price Target: n/a
Current: $3.10
Upside: -
Maintains: Strong Buy
Price Target: $50$65
Current: $47.84
Upside: +35.87%
Downgrades: Market Perform
Price Target: n/a
Current: $7.31
Upside: -
Upgrades: Outperform
Price Target: $255
Current: $303.01
Upside: -15.84%
Assumes: Buy
Price Target: $32
Current: $4.22
Upside: +658.29%
Downgrades: Sell
Price Target: n/a
Current: $162.30
Upside: -